- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04748939
Shingrix hos patienter med reumatiske sygdomme: en dobbeltblind placebo-kontrolleret RCT
Sikkerhed og immunogenicitet af en rekombinant underenhed herpes zoster-vaccine hos patienter med reumatiske sygdomme, der gennemgår immunsuppressive eller biologiske/målrettede DMARD-terapier: et dobbeltblindt randomiseret placebokontrolleret forsøg
A double-blind randomized controlled trial on the safety and immunogenicity of the recombinant subunit herpes zoster vaccine, Shingrix, in patients with rheumatic diseases undergoing immunosuppressive or biologic/targeted DMARD therapies
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
A double-blind randomized controlled trial on the safety and immunogenicity of the recombinant subunit herpes zoster vaccine, Shingrix, in patients with rheumatic diseases undergoing immunosuppressive or biologic/targeted DMARD therapies.
Duration of study: 60 weeks
Undersøgelsestype
Fase
- Fase 4
Kontakter og lokationer
Studiesteder
-
-
-
Hong Kong, Kina
- Department of Medicine, Tuen Mun Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion criteria for patients:
-
Patients with a diagnosis of rheumatic or immune-mediated diseases eg. SLE, RA, PSA, SpA, inflammatory myopathies, ANCA-related and large vessel vasculitides
-
Age ≥18 years
-
Stable or reducing doses of any the following immunosuppressive regimens within 4 weeks of study entry:
- Prednisolone ≥20mg/kg/day ± mycophenolate mofetil, azathioprine or the calcineurin inhibitors
- Cyclophosphamide (intravenous pulses or daily oral)
- B-cell depleting biological agents and their biosimilars eg. belimumab, anti-CD20 agents (next scheduled dose should be arranged to at least 12 weeks after study entry for rituximab or obinutuzumab)
- Anti-TNFα biological agents and their biosimilars eg. infliximab, etanercept, adalimumab, golimumab, certolizumab
- Anti-interleukin-6 biological agents eg. tocilizumab, sarilumab
- Other biological agents eg. abatacept, ustekinumab, secukinumab, ixekizumab
- The JAK inhibitors eg. tofacitinib, baricitinib, upadacitinib
-
Female patients with reproductive potential are allowed to participate in this study provided that they are willing to practice contraception for until at least 12 months after vaccination
-
Willing to comply with all study procedures
Exclusion criteria for patients:
- Active infection, including upper respiratory tract infection
- Active HZ infection
- Active untreated tuberculosis
- HIV infection
- History of HZ or varicella vaccination in the past
- History of allergy to any vaccines
- Patients who are pregnant or plan to become pregnancy within one year of study entry
- Lactating women
- Patients who cannot give a written consent (mentally incapable or illiterate)
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Tredobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: vaccine
Shingrix vaccine |
vaccine administration
Andre navne:
|
|
Placebo komparator: placebo
normal saline injection (0.5mL) |
vaccine administration
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
humoral immune response to Shingrix
Tidsramme: week 12 (compared with baseline)
|
proportion of patients with 4x fold increase in anti-gE antibody titer |
week 12 (compared with baseline)
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Humoral immune response
Tidsramme: week 52
|
proportion of patients with 4x fold increase in anti-gE antibody titer |
week 52
|
|
adverse events
Tidsramme: 7 days after injection
|
solicited |
7 days after injection
|
|
adverse events
Tidsramme: 4 weeks after injection
|
unsolicited |
4 weeks after injection
|
|
flares of underlying diseases
Tidsramme: week 26 and 60
|
disease flares |
week 26 and 60
|
|
herpes zoster infection
Tidsramme: week 60
|
herpes zoster infection |
week 60
|
|
cell mediated response to vaccine
Tidsramme: week 12 from baseline
|
in 40 patients (20 from each arm); number of IFNγ-secreting CD4+ T cell colonies on ELISPOT assay |
week 12 from baseline
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Chi Chiu Mok, Tuen Mun Hospital
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- NTWCShingrixstudy
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .